Patented Medicine Prices Review Board CPI Initiative. . Tanya Potashnik: A/Director, Policy and Economic Analysis October, 2013 . CPI-Initiative - Background.
Tanya Potashnik: A/Director, Policy and Economic Analysis
The Consumer Price Index methodology was introduced as part of the Board´s Guidelines on Excessive Prices in 1989, in application of the CPI pricing factor listed in the now sub-section 85(1)(d) of the Patent Act.
The CPI is one of four pricing factors the Board must take into consideration when determining whether the price of a patented drug product is excessive.
The CPI Adjustment Methodology was last amended in 1994 and applies to ‘existing’ patented drug products in accordance with the Board´s Guidelines.
To allow patentees to set prices reflective of current CPI rates, the Board´s CPI methodology provides for the calculation of the CPI Adjustment factors based on forecast changes in the CPI.
These forecasted CPI Adjustment factors are published each year in the April NEWSletter.
Patentees are able to use these published forecasted factors to increase their prices up to the allowable maximum. The actual CPI values are obtained in January of the following calendar year, which are used by Board Staff in accordance with the Guidelines, to calculate the National Non-Excessive Average Price (N-NEAP) for the year.
In alignment with the Government’s Red Tape Reduction Plan and Economic Action Plan, the PMPRB has committed to examining its price review process to identify possible ways to reduce the regulatory burden on patentees and increase efficiency without adversely affecting its mandate to protect consumer interests.
The Board consulted stakeholders in a Notice and Comment issued May 2013 on the two priority initiatives to amend the CPI-Adjustment Methodology and the filing requirements.
12 stakeholders provided submissions.
Feedback on both proposals was generally supportive.
Stakeholders were overall supportive of the CPI initiative.
3 Broad Areas of Concern:
Details on how actual lagged CPI would be determined and when it would be communicated to stakeholders.
Assurance that the use of actual lagged CPI was in line with provincial drug plan policies on price changes.
Patentees did not want to be in a position where the ability to raise prices was curtailed during transition period.
The current methodology will be maintained and the CPI used will be the actual lagged CPI that is available in the 3rd week of January
The new CPI initiative is proposed for 2015 implementation
The January 2014 NEWSletter will announce the actual CPI for the 2013 year, a 12-month period ending in December 2013. This actual lagged 2013 CPI will be used to calculate the CPI-Adjustment Factors for 2015
In the April 2013 NEWsletter, patentees were provided with the 2014 forecast CPI-Adjustment Factors. For 2014, the existing CPI-Adjustment Methodology will be applied
The CPI initiative is proposed for implementation for 2015, as a result transitional measures are not being contemplated
Removal of C.12.3 Review of Prices of Existing Patented Drug Products as it no longer applies.
C.12.3 In the event that the actual change in the CPI is less than the forecast CPI and an apparent excessive price arises solely due to the patentee´s reliance on the forecast CPI, the price will not be presumed to be excessive. The patentee is expected to comply with the actual CPI in all subsequent reporting periods, and the application of the CPI-Adjustment Methodology for the forecasted year will be based on the actual change in the CPI for that year. The result for patentees that took price increases based on the forecast inflation will be that the actual change in the CPI for the forecasted year will be used to calculate the next year´s National and Market-Specific Non-Excessive Average Prices.